Wechselwirkungen · Sovaldi
Sovaldi 400 mg film-coated tablets Sovaldi 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-129763 · Präparat HOS-096803
Sofosbuvir is a nucleotide prodrug. After oral administration of Sovaldi, sofosbuvir is rapidly absorbed and subject to extensive first-pass hepatic and intestinal metabolism. Intracellular hydrolytic prodrug cleavage catalysed by enzymes including carboxylesterase 1 and sequential phosphorylation steps catalysed by nucleotide kinases result in formation of the pharmacologically active uridine nucleoside analogue triphosphate. The predominant inactive circulating metabolite GS-331007 that accounts for greater than 90% of drug-related material systemic exposure is formed through pathways sequential and parallel to formation of active metabolite. The parent sofosbuvir accounts for approximately 4% of drug-related material systemic exposure (see section 5.2). In clinical pharmacology studies, both sofosbuvir and GS-331007 were monitored for purposes of pharmacokinetic analyses.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): triphosphate (HOS-109819) uridine (HOS-085192)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-22T14:59:00Z · SHA-256 66b8a9d8a664c3fd4fadbfdcf1cd8c6e93c3430d5e235cfa78b2847b24a28727 · Passage ab556887163921e3de959dedb2c53a699c6d6e2aff931920c005b7b2e8863d0f · Zeichen 0–887 im Abschnitt